Skip to main
MDT
MDT logo

Medtronic (MDT) Stock Forecast & Price Target

Medtronic (MDT) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 14%
Buy 57%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Medtronic is anticipated to increase its FY26 revenue and EPS guidance due to strong first-quarter performance, favorable currency dynamics, and mitigated tariffs. The launch of the Affera product, which is expected to outperform competing systems, is projected to drive enhanced growth in the Cardiac Ablation segment. Additionally, the company's commitment to technological advancements aims to improve procedure outcomes, contributing to a positive outlook on its financial trajectory.

Bears say

The financial outlook for Medtronic appears negative due to anticipated revenue growth slowing to low-single digits, primarily attributed to unsuccessful new product launches and loss of market share in key categories, which could lead to below-consensus earnings. Additionally, the company faces significant risks, including competition from new product launches, disappointing sales performance, and potential adverse currency impacts that may further pressure margins. Furthermore, while acquisitions aimed at enhancing growth could prove beneficial in the long term, they may result in near-term dilution, complicating the company's earnings growth trajectory.

Medtronic (MDT) has been analyzed by 14 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 57% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medtronic (MDT) Forecast

Analysts have given Medtronic (MDT) a Buy based on their latest research and market trends.

According to 14 analysts, Medtronic (MDT) has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medtronic (MDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.